Lexaria Bioscience Corp. - Common Stock (LEXX)

LEXX stock results show that Lexaria Bioscience missed analyst estimates for earnings per share and missed on revenue for the third quarter of 2024.

Some penny stocks can be diamonds in the rough. These A-rated penny stocks are all solid picks for a portfolio this month.

A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation.

Lexaria Bioscience shares are trading lower by 6.5% Thursday morning. The company finalized agreements for a registered direct offering.

It's time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning!

For a growth investor, one of the top advantages of A-rated penny stocks is that they have the potential for oversized profits.

LEXX stock results show that Lexaria Bioscience beat analyst estimates for earnings per share the second quarter of 2024.

Shares of Asana, Inc. (NYSE: ASAN) fell sharply during Tuesday’s session following soft FY25 revenue guidance.

Lexaria Bioscience just reported results for the first quarter of 2024.

Gainers

Lexaria Bioscience Corp (NASDAQ: LEXX) announces that its animal study HOR-A22-1 has been completed, showing significant enhancement in the oral delivery of the